Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions

Journal of Medicinal Chemistry

Volumn 42, Issue 4, 1999, Pages 761-768

  Cervini, Laura ^a   Theobald, Paula ^a   Corrigan, Anne ^a   Craig, A Grey ^a   Rivier, Catherine ^a   Vale, Wylie ^a   Rivier, Jean ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR DERIVATIVE; LEUCINE; SAUVAGINE; SERINE; UROCORTIN; UROTENSIN;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CORTICOTROPIN RELEASE; DIMERIZATION; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RAT; RECEPTOR BINDING;

EID: 0033602255     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980607e     Document Type: Article

References (51)

1. Rivier, J.; Lahrichi, S. L.; Gulyas, J.; Erchegyi, J.; Koerber, S. C.; Craig, A. G.; Corrigan, A.; Rivier, C.; Vale, W. Minimal-size, constrained corticotropin releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges. J. Med. Chem. 1998, 41, 2614-2620.
2. Rivier, J.; Rivier, C.; Vale, W. Synthetic competitive antagonists of corticotropin releasing factor: Effect on ACTH secretion in the rat. Science 1984, 224, 889-891.
3. Rivier, J.; Gulyas, J.; Corrigan, A.; Craig, A. G.; Martinez, V.; Taché, Y.; Vale, W.; Rivier, C. Astressin analogues (CRF antagonists) with extended duration of action in the rat. J. Med. Chem. 1998, 41, 5012-5019.
4. Vale, W.; Spiess, J.; Rivier, C.; Rivier, J. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science 1981, 213, 1394-1397.
5. Rivier, C. L.; Plotsky, P. M. Mediation by corticotropin-releasing factor (CRF) of adenohypophysial hormone secretion. Annu. Rev. Physiol. 1986, 48, 475-494.
6. Munck, A.; Guvre, P. M. Glucocorticoid physiology, pharmacology and stress. Adv. Exp. Med. Biol. 1986, 196, 81-96.
7. Dallman, M. F.; Strack, A. M.; Akana, S. F.; Bradbury, M. J.; Hanson, E. S.; Scribner, K. A.; Smith, M. Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. Front. Neuroendocrinol. 1993, 14, 303-347.
8. Vale, W. Corticotropin-Releasing Factor; John Wiley & Sons: West Sussex, England, 1993; Ciba Foundation Symposium 172, p 357.
9. Chen, R.; Lewis, K. A.; Perrin, M. H.; Vale, W. W. Expression cloning of a human corticotropin releasing factor (CRF) receptor. Proc. Natl. Acad. Sci., U.S.A. 1993, 90, 8967-8971.
10. Chang, C. P.; Pearse, R. V., II.; O'Connell, S.; Rosenfeld, M. G. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 1993, 11, 1187-1195.
11. Perrin, M.; Donaldson, C.; Chen, R.; Blount, A.; Berggren, T.; Bilezikjian, L.; Sawchenko, P.; Vale, W. Identification of a second CRF receptor gene and characterization of a cDNA expressed in heart. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2969-2973.
12. Kishimoto, T.; Pearse, R. V., II.; Lin, C. R.; Rosenfeld, M. G. A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1108-1112.
13. Vita, N.; Laurent, P.; Lefort, S.; Chalon, P.; Lelias, J. M.; Kaghad, M.; Le, F. G.; Caput, D.; Ferrara, P. Primary structure and functional expression of mouse pituitary and human brain corticotropin releasing factor receptors. FEBS Lett. 1993, 335 1-5.
14. Lovenberg, T. W.; Liaw, C. W.; Grigoriadis, D. E.; Clevenger, W.; Chalmers, D. T.; DeSouza, E. B.; Oltersdorf, T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 836-840.
15. Perrin, M. H.; Donaldson, C. J.; Chen, R.; Lewis, K. A.; Vale, W. W. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 1993, 133, 3058-3061.
16. Potter, E.; Behan, D. P.; Fischer, W. H.; Linton, E. A.; Lowry, P. J.; Vale, W. W. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins. Nature 1991, 349, 423-426.
17. Koerber, S. C.; Gulyas, J.; Lahrichi, S. L.; Corrigan, A.; Craig, A. G.; Rivier, C.; Vale, W. W.; Rivier, J. Constrained corticotropin releasing factor (CRF) agonists and antagonists with i-(i+3) GluXaa-DXbb-Lys bridges. J. Med. Chem. 1998, 41, 5002-5011.
18. Gulyas, J.; Rivier, C.; Perrin, M.; Koerber, S. C.; Sutton, S.; Corrigan, A.; Lahrichi, S. L.; Craig, A. G.; Vale, W. W.; Rivier, J. Potent, structurally constrained agonists and competitive antagonists of corticotropin releasing factor (CRF). Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 10575-10579.
19. Vale, W.; Grant, G.; Rivier, J.; Monahan, M.; Amoss, M.; Blackwell, R.; Burgus, R.; Guillemin, R. Synthetic polypeptide antagonists of the hypothalamic luteinizing hormone releasing factor. Science 1972, 176, 933-934.
20. Hocart, S. J.; Jain, R.; Murphy, W. A.; Taylor, J. E.; Morgan, B.; Coy, D. H. Potent antagonists of somatostatin: Synthesis and biology. J. Med. Chem. 1998, 41, 1146-1154.
21. Martinez, J.; Bali, J.-P.; Rodriguez, M.; Castro, B.; Magous, R.; Laur, J.; Ligon, M.-F. Synthesis and biological activities of some pseudo-peptide analogues of tetragastrin: the importance of the peptide backbone. J. Med. Chem. 1985, 28, 1874-1879.
22. 2 and N-terminal aromatic residues. J. Med. Chem. 1994, 37, 439-445.
23. Manning, M.; Lammek, B.; Bankowski, K.; Seto, J.; Sawyer, W. H. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin. J. Med. Chem. 1985, 28, 1485-1491.
24. Daniels, A. J.; Matthews, J. E.; Slepetis, R. J.; Jansen, M.; Viveros, O. H.; Tadepalli, A.; Harrington, W.; Heyer, D.; Landavazo, A.; Leban, J. J.; Spaltenstein, A. High-affinity neuropeptide Y receptor antagonists. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 9067-9071.
25. 2 by substitution of PTH amino acids at positions 10 and 11. Endocrinology 1990, 127, 491-493.
26. Rivier, J.; Rivier, C.; Galyean, R.; Miranda, A.; Miller, C.; Craig, A. G.; Yamamoto, G.; Brown, M.; Vale, W. Single point D-substituted corticotropin releasing factor analogues: Effects on potency and physicochemical characteristics. J. Med. Chem. 1993, 36, 2851-2859.
27. Kornreich, W. D.; Galyean, R.; Hernandez, J.-F.; Craig, A. G.; Donaldson, C. J.; Yamamoto, G.; Rivier, C.; Vale, W. W.; Rivier, J. E. Alanine series of ovine corticotropin releasing factor (oCRF): a structure-activity relationship study. J. Med. Chem. 1992, 35, 1870-1876.
28. Stewart, J. M.; Young, J. D. Solid-Phase Peptide Synthesis. In Solid-Phase Peptide Synthesis; Pierce Chemical Co.: Rockford, IL, 1984.
29. Märki, W.; Spiess, J.; Taché, Y.; Brown, M.; Rivier, J. E. Total solid-phase synthesis of porcine gut gastrin releasing peptide (GRP), a mammalian bombesin. J. Am. Chem. Soc. 1981, 103, 3178-3185.
30. Felix, A. M.; Heimer, E. P.; Wang, C. T.; Lambros, T. J.; Fournier, A.; Mowles, T. F.; Maines, S.; Campbell, R. M.; Wegrzynski, B. B.; Toome, V.; Fry, D.; Madison, V. S. Synthesis, biological activity and conformational analysis of cyclic GRF analogues. Int. J. Pept. Protein Res. 1988, 32, 441-454.
31. Miranda, A.; Koerber, S. C.; Gulyas, J.; Lahrichi, S.; Craig, A. G.; Corrigan, A.; Hagler, A.; Rivier, C.; Vale, W.; Rivier, J. Conformationally restricted competitive antagonists of human/ rat corticotropin-releasing factor. J. Med. Chem. 1994, 37, 1450-1459.
32. Hocart, S. J.; Murphy, W. A.; Coy, D. H. Analogues of growth hormone-releasing factor (1-29) amide containing the reduced peptide bond isostere in the N-terminal region. J. Med. Chem. 1990, 33, 1954-1958.
33. Fehrentz, J.-A.; Castro, B. An efficient synthesis of optically active α-(tert-butoxycarbonylamino)-aldehydes from α-amino acids. Synthesis 1983, 676-678.
34. Jiang, G.; Miller, C.; Koerber, S. C.; Porter, J.; Craig, A. G.; Bhattacharjee, S.; Kraft, P.; Burns, T. P.; Campen, C. A.; Rivier, C. L.; Rivier, J. E. Betidamino acid scan of the GnRH antagonist Acyline. J. Med. Chem. 1997, 40, 3739-3748.
35. Rivier, J. E.; Jiang, G.-C.; Koerber, S. C.; Porter, J.; Craig, A. G.; Hoeger, C. Betidamino acids: Versatile and constrained scaffolds for drug discovery. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2031-2036.
36. Jiang, G.-C.; Simon, L.; Rivier, J. E. Orthogonally protected N-methyl-substituted α-aminoglycines. Protein Pept. Lett. 1996, 3, 219-224.
37. Hoeger, C. A.; Galyean, R. F.; Boublik, J.; McClintock, R. A.; Rivier, J. E. Preparative reversed phase high performance liquid chromatography. II. Effects of buffer pH on the purification of synthetic peptides. Biochromatography 1987, 2, 134-142.
38. Rivier, J.; Spiess, J.; Vale, W. Characterization of rat hypothalamic corticotropin-releasing factor. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 4851-4855.
39. Vaughan, J. M.; Donaldson, C.; Bittencourt, J.; Perrin, M. H.; Lewis, K.; Sutton, S.; Chan, R.; Turnbull, A.; Lovejoy, D.; Rivier, C.; Rivier, J.; Sawchenko, P. E.; Vale, W. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995, 378, 287-292.
40. Beyermann, M.; Fechner, K.; Furkert, J.; Krause, E.; Bienert, M. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor. J. Med. Chem. 1996, 39, 3324-3330.
41. Hernandez, J.-F.; Kornreich, W.; Rivier, C.; Miranda, A.; Yamamoto, G.; Andrews, J.; Taché, Y.; Vale, W. W.; Rivier, J. E. Synthesis and relative potencies of new constrained CRF antagonists. J. Med. Chem. 1993, 36, 2860-2867.
42. Coy, D. H.; Heinz-Erian, P.; Jiang, N.-Y.; Sasaki, Y.; Taylor, J.; Moreau, J.-P.; Wolfrey, W. T.; Gardner, J. D.; Jensen, R. T. Probing peptide backbone function in bombesin. J. Biol. Chem. 1988, 263, 5056-5060.
43. Perrin, M. H.; Sutton, S. W.; Cervini, L.; Rivier, J. E.; Vale, W. W. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of CRF receptors. J. Pharmacol. Exp. Ther. 1999, 288, 729-734.
44. Rudinger, J.; Pliska, V.; Krejci, I. Oxytocin analogues in the analysis of some phases of hormone action. In Recent Progress in Hormone Research; Academic Press: New York, 1972; Vol. 28, pp 131-172.
45. Kirby, D. A.; Wang, W.; Gershengorn, M. C.; Rivier, J. E. Analogues of thyrotropin-releasing hormone using an aminoglycine based template. Peptides 1998, 19, 1679-1683.
46. Meyer, J.-P.; Gillespie, T. J.; Horn, S.; Hruby, V. J.; Davis, T. P. In vitro stability of some reduced peptide bond pseudopeptide analogues of dynorphin A. Peptides 1995, 16, 1215-1219.
47. Merrifield, R. B. Solid-phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 1963, 85, 2149-2154.
48. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
49. Felix, A. M.; Wang, C.-T.; Heimer, E. P.; Fournier, A. Applications of BOP reagent in solid-phase synthesis. II. Solid-phase side-chain to side-chain cyclizations using BOP reagent. Intl. J. Pept. Protein Res. 1988, 31, 231-238.
50. 2NAc peptide bond isosteres on the antagonistic and histamine releasing activities of a luteinizing hormone-releasing hormone analogue. J. Med. Chem. 1988, 31, 1820-1824.
51. Rodbard, D. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin. Chem. 1974, 20, 1255-1270.